Your browser doesn't support javascript.
loading
Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons.
Ranganath, Nischal; O'Horo, John C; Challener, Douglas W; Tulledge-Scheitel, Sidna M; Pike, Marsha L; O'Brien, Michael; Razonable, Raymund R; Shah, Aditya.
Afiliação
  • Ranganath N; Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • O'Horo JC; Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Challener DW; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Tulledge-Scheitel SM; Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Pike ML; Division of Community Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • O'Brien M; Department of Nursing, Mayo Clinic, Rochester, Minnesota, USA.
  • Razonable RR; Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
  • Shah A; Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Clin Infect Dis ; 76(3): e537-e539, 2023 02 08.
Article em En | MEDLINE | ID: mdl-35698452
ABSTRACT
In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ritonavir / COVID-19 Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ritonavir / COVID-19 Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article